Document Detail

Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
MedLine Citation:
PMID:  23370164     Owner:  NLM     Status:  Publisher    
Aim: Longitudinal study aimed to evaluate the antihypertensive efficacy, safety and the effect on cardiac damage of Aliskiren, administered to a group of high-risk hypertensive patients with mild impairment of renal function and uncontrolled blood pressure (BP) despite a two-drug antihypertensive treatment. Methods: One hundred and six patients (56 men and 50 females) aged 61.9±12.7 years, were assigned to receive Aliskiren 150-300 mg once-daily for 12 months. Clinic BP measurements were taken at every follow-up visit (1st, 6th and 12th month), while biochemical tests, estimated glomerular filtration rate (eGFR), 24-hours ambulatory BP measurements (ABMP) and echocardiography were evaluated at baseline and at the end of follow-up. Analysis of variance for repeated measures compared BP, left ventricular mass index (LVMI) and eGFR values changes. Results: A significant reduction (all P<0.0001) of clinic systolic (-28.6 mmHg) and diastolic (-12.8 mmHg) BP values, mean 24h-systolic (-12.3 mmHg) and 24h-diastolic (-6.5 mmHg), day-time systolic (-11.5 mmHg) and diastolic (-6.4 mmHg), night-time systolic (-11.9 mmHg) and diastolic (-7 mmHg) ABPM values and in the use of antihypertensive drugs was observed (3.0±0.9 vs. 2.0±0.7, p=0.01). LVMI was significantly reduced (130.2±36.1 vs. 115.9±33.4 g/m2, P<0.0001); eGFR was steady (75.3±17.3 vs. 73.1±21.5 ml/min/1.73m2, P>0.05). Putative adverse events caused withdrawal of 7 subjects (6 for gastrointestinal disturbances, 1 for alopecia). Conclusion: Aliskiren was effective in decreasing both clinical and ABPM values and in reducing LVMI in both genders without any influence on eGFR. The treatment resulted safe, even in combination with ACE-inhibitors and angiotensin II receptor blockers. A significant reduction in the use of concomitant antihypertensive drugs was observed.
A Mazza; D Montemurro; M Zuin; L Schiavon; S Zorzan; S Chondrogiannis; A Ferretti; E Ramazzina; D Rubello
Related Documents :
7172754 - Garlic as a natural agent for the treatment of hypertension: a preliminary report.
25108554 - First in vivo application and evaluation of a novel method for non-invasive estimation ...
7353414 - Hemodynamic response to isometric handgrip in acute myocardial infarction.
11862274 - Metoclopramide-induced vascular hyperreactivity: a comparative study between normotensi...
6497654 - Hypotensive effects of hydroxylamine in intact anesthetized dogs and cats.
8821224 - A review of seven support surfaces with emphasis on their protection of the spinally in...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-01
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  -     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Internal Medicine, Santa Maria della Misericordia Hospital Rovigo, Italy -
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neurological prognostication after cardiac arrest-Recommendations from the Swedish Resuscitation Cou...
Next Document:  Effect of polymer ligand structures on fluorescence of gold clusters prepared by photoreduction.